Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 3, 2012, Pages

  Kim, Young Mee ^a   Jeong, In Hye ^a   Pyo, Hongryull ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Celecoxib; Chk1; COX 2; Radiosensitization; UCN 01

Indexed keywords

CELECOXIB; CHK1; COX-2; RADIO-SENSITIZATION; UCN-01;

CELL CULTURE; DRUG INTERACTIONS; FLOW CYTOMETRY; GROWTH (MATERIALS); IONIZING RADIATION; TISSUE;

RADIOTHERAPY;

7 HYDROXYSTAUROSPORINE; CELECOXIB;

ADD ON THERAPY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; LUNG CANCER; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; RADIOSENSITIZATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; G2 PHASE; HUMANS; MITOSIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZOLES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; STAUROSPORINE; SULFONAMIDES; TUMOR STEM CELL ASSAY;

EID: 84862798208     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.001     Document Type: Article

References (14)

1. D. Sampath, J. Cortes, and Z. Estrov Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood 107 2006 2517 2524
2. Y. Dai, S. Chen, and R. Shah Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo Blood 117 2011 1947 1957
3. E.A. Sausville, S.G. Arbuck, and R. Messmann Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms J Clin Oncol 19 2001 2319 2333
4. C. Dudgeon, P. Wang, and X. Sun PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01 Mol Cancer Ther 9 2011 2893 2902
5. P.M. Fracasso, K.J. Williams, and R.C. Chen A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies Cancer Chemother Pharmacol 67 2010 1225 1237
6. M.J. Edelman, K.S. Bauer Jr., and S. Wu Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors Clin Cancer Res 13 2007 2667 2674
7. Y.M. Kim, E.J. Lee, and S.Y. Park Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation Mol Cancer Res 7 2009 1158 1168
8. J.S. Park, H.J. Jun, and M.J. Cho Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells Clin Cancer Res 12 2006 4989 4999
9. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 2006 621 681
10. M.C. Berenbaum A method for testing for synergy with any number of agents J Infect Dis 137 1978 122 130
11. H.J. Jun, Y.M. Kim, and S.Y. Park Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib Int J Radiat Oncol Biol Phys 75 2009 225 234
12. H. Pyo, H. Choy, and G.P. Amorino A Selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2 Clin Cancer Res 7 2001 2998 3005
13. N.M. Davies, A.J. McLachlan, and R.O. Day Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor Clin Pharmacokinet 38 2000 225 242
14. K.F. On, Y. Chen, and H.T. Ma Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01 Mol Cancer Ther 10 2011 784 794